Antineoplastic Agents, Phytogenic
Leukemia P388
Amaryllidaceae Alkaloids
Ellipticines
Doxorubicin
Drug Screening Assays, Antitumor
Antibiotics, Antineoplastic
Bryostatins
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Ancitabine
Neoplasms
Gallium
Depsipeptides
Tumor Cells, Cultured
Cisplatin
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Paclitaxel
6-Mercaptopurine
Apoptosis
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Aminoacridines
Epothilones
Cell Survival
Molecular Structure
Lactones
Daunorubicin
Fluorouracil
Bleomycin
Dose-Response Relationship, Drug
Etoposide
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Prodrugs
Drug Evaluation, Preclinical
Drug Evaluation
Cell Division
Xenograft Model Antitumor Assays
Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Macrolides
Neoplasms, Experimental
Methotrexate
Camptothecin
Cell Cycle
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Mice, Nude
HL-60 Cells
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Enzyme Inhibitors
Drug Administration Schedule
Isoquinolines
Neoplasm Transplantation
Biotransformation
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
Drug Interactions
DNA Damage
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Stereoisomerism
Clinical Trials as Topic
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Ovarian Neoplasms
Caspases
A family of intracellular CYSTEINE ENDOPEPTIDASES that play a role in regulating INFLAMMATION and APOPTOSIS. They specifically cleave peptides at a CYSTEINE amino acid that follows an ASPARTIC ACID residue. Caspases are activated by proteolytic cleavage of a precursor form to yield large and small subunits that form the enzyme. Since the cleavage site within precursors matches the specificity of caspases, sequential activation of precursors by activated caspases can occur.
Taxoids
Structure-Activity Relationship
DNA
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Phospholipid Ethers
Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues.
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Reactive Oxygen Species
Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.
Cells, Cultured
Gloves, Protective
Coverings for the hands, usually with separations for the fingers, made of various materials, for protection against infections, toxic substances, extremes of hot and cold, radiations, water immersion, etc. The gloves may be worn by patients, care givers, housewives, laboratory and industrial workers, police, etc.
Aster Plant
Occupational Exposure
Treatment Outcome
Medical Secretaries
Oncology Nursing
Sulindac
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
Protective Devices
Protective Clothing
Equipment Contamination
Amsacrine
Decontamination
Phlebitis
Environmental Monitoring
Hazardous Substances
Inhibitory Concentration 50
Carcinoma, Ehrlich Tumor
Floxuridine
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Drug Compounding
2-Propanol
Tumor Stem Cell Assay
Carmustine
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Cytarabine
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Topoisomerase II Inhibitors
Drug Resistance, Multiple
Farnesyltranstransferase
Oncology Service, Hospital
Comet Assay
A genotoxicological technique for measuring DNA damage in an individual cell using single-cell gel electrophoresis. Cell DNA fragments assume a "comet with tail" formation on electrophoresis and are detected with an image analysis system. Alkaline assay conditions facilitate sensitive detection of single-strand damage.
Drugs, Investigational
Isocoumarins
Nitrogen Mustard Compounds
Nurses
Suramin
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
Alkaloids
Plant Extracts
Mitomycin
Azacitidine
DNA Adducts
DNA Topoisomerases, Type II
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Pharmacists
Lethal Dose 50
Gene Expression Regulation, Neoplastic
Mutagenicity Tests
Metabolic Detoxication, Drug
HT29 Cells
Blotting, Western
Hydrazones
Alkylating Agents
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Mammary Neoplasms, Experimental
Organoplatinum Compounds
Octreotide
Glutathione Transferase
Mitomycins
Dehydroascorbic Acid
Anthracyclines
Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. (1/2596)
Interleukin 6 (IL-6) is a multifunctional cytokine. Recent reports suggest that circulating IL-6 secreted from tumour cells plays an important role in cancer-induced cachexia. Medroxyprogesterone acetate (MPA) has been used as an endocrine therapeutic agent for patients with breast cancer. It has been suggested that MPA decreases serum IL-6 levels and preserves the bodyweight of patients with advanced breast cancer. However, the mechanisms of action responsible for the anticachectic effect of MPA have not been elucidated. Therefore, the effects of MPA on IL-6 secretion were studied both in vitro and in vivo using a human breast cancer cell line, KPL-4, which secretes IL-6 into medium and induces cachexia when injected into female nude mice. MPA (10-1000 nM) dose-dependently decreased basal IL-6 secretion into medium, and also suppressed tumour necrosis factor (TNF-alpha)-induced IL-6 secretion. Both basal and TNF-alpha-induced IL-6 mRNA levels were dose-dependently lowered by MPA. Moreover, intramuscular injections of MPA (100 mg kg(-1) twice a week) into nude mice bearing KPL-4 transplanted tumours significantly decreased serum IL-6 levels without affecting tumour growth and preserved the bodyweight of recipient mice. These findings suggest that suppression of IL-6 secretion from tumour cells, at least in part, causes the anticachectic effect of MPA. (+info)The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. (2/2596)
Somatostatin and its analogs can inhibit growth in several cell types, in part by interfering with insulin-like growth factor-I (IGF-I) signaling. Our previous studies point to the importance of paracrine and autocrine IGF-I in the support of growth and survival of human multiple myeloma (MM) cell lines. In this report, we have investigated the potential role of a somatostatin analog, octreotide, in regulating growth and/or survival in MM. The results show that all MM cell lines express functional somatostatin receptors (sst). The MM cell lines express the subtypes sst2, sst3, and predominantly sst5 as determined by reverse-transcriptase polymerase chain reaction and fluorescence-activated cell sorter analysis. Octreotide inhibited the growth of both the interleukin-6 (IL-6)-dependent and the IL-6-independent MM cell lines. The effect is mainly cytostatic, resulting in 25% to 45% growth inhibition, and in three of eight of the MM cell lines a weak induction of apoptosis was recorded. Our results also show that octreotide may act as an inducer of apoptosis in primary B-B4(+) plasma cells isolated from bone marrow of MM patients. In conclusion, the results show a novel pathway for growth inhibition of MM cells: the activation of somatostatin receptor signaling. (+info)Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. (3/2596)
Human breast tumors that are initially responsive to tamoxifen (TAM) eventually relapse during treatment. Estrogen receptor (ER) expression and function are often preserved in these tumors, and clinical evidence suggests that this relapse may be related to TAM's known agonistic properties. ER can interact with the activator protein-1 (AP-1) transcription factor complex through protein-protein interactions that are independent of ER DNA binding and, in certain ER-positive cells, this may allow TAM to exert an agonist response on AP-1-regulated genes. We, therefore, assessed both AP-1 DNA binding and the known AP-1 activating enzyme, c-Jun NH2-terminal kinase (JNK), in a panel of 30 ER-positive primary human breast tumors with acquired TAM resistance, as compared to a matched panel of 27 untreated control ER-positive breast tumors and a separate control set of 14 primary tumors, which included 7 ER-positive tumors that were growth-arrested by 3 months of preoperative TAM. AP-1 DNA binding activity was measured from cryopreserved tumor extracts using a labeled oligonucleotide probe containing a consensus AP-1 response element by electrophoretic mobility shift assay. JNK was first extracted from the tumor lysates by incubation over a Sepharose-bound c-Jun(1-89) fusion protein, and its activity was then measured by chemiluminescent Western blot by detection of the phosphorylated product using a phospho-Jun(Ser-63)-specific primary antibody. The set of control ER-positive breast tumors growth arrested by TAM showed no significant difference from untreated control tumors in their AP-1 DNA binding and JNK activities. In contrast, there was a significant (P < 0.001) increase in mean AP-1 DNA binding activity for the panel of ER-positive TAM-resistant (TAM-R) tumors as compared to its matched control panel of untreated tumors. Mean JNK activity in the TAM-R tumors was also significantly higher than that found in the untreated tumors (P = 0.038). Overall, there was no significant correlation between JNK activity and AP-1 DNA binding; however, regression analysis showed that, for any given level of JNK activity, the TAM-R tumors possessed a 3.5-fold increase in AP-1 DNA binding activity as compared to the untreated tumors. These findings indicate that, when compared to untreated ER-positive primary breast tumors, TAM-R tumors demonstrate significantly increased levels of AP-1 DNA binding and JNK activity, consistent with experimental models suggesting that TAM-stimulated ER-positive tumor growth may be mediated by enhanced AP-1 transcriptional activity. These observations support the need for further evaluation of these markers in breast tumors as predictors of TAM resistance. (+info)In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. (4/2596)
Adenoviral vectors, encoding genes for cell surface antigens or receptors, have been used to induce their high level expression on tumor cells in vitro and in vivo. These induced antigens and receptors can then be targeted with radiolabeled antibodies or peptides for potential radiotherapeutic applications. The purpose of this study was to determine a dosing schema of an adenoviral vector encoding the human somatostatin receptor subtype 2 (AdCMVhSSTr2) for achieving the highest tumor localization of [(111)In]-DTPA-D-Phe1-octreotide, which binds to this receptor, in a human ovarian cancer model as a prelude to future therapy studies. AdCMVhSSTr2 was produced and used to induce hSSTr2 on A427 human nonsmall cell lung cancer cells and on SKOV3.ipl human ovarian cancer cells in vitro, as demonstrated by competitive binding assays using [125I]-Tyr1-somatostatin and [(111)In]-DTPA-D-Phe1-octreotide. Mice bearing i.p. SKOV3.ip1 tumors administered 1 x 10(9) plaque-forming units of AdCMVhSSTr2 i.p. 5 days after tumor cell inoculation, followed by an i.p. injection of [(111)In]-DTPA-D-Phe1-octreotide 2 days later, showed a range of 15.3-60.4% median injected dose/gram (ID/g) in tumor at 4 h after injection compared with 3.5% ID/g when [125I]-Tyr1-somatostatin was administered and 0.3% ID/g when the negative control peptide [125I]-mIP-bombesin was administered. Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells. In another set of experiments, the tumor localization of [(111)In]-DTPA-D-Phe1-octreotide was not different 1, 2, or 4 days after AdCMVhSSTr2 injection (31.8, 37.7, and 40.7% ID/g, respectively; P = 0.88), indicating that multiple injections of radiolabeled peptide can be administered with equivalent uptake over a 4-day period. [(111)In]-DTPA-D-Phe1-octreotide tumor localization in animals administered AdCMVhSSTr2 on consecutive days or 2 days apart was 22.4% ID/g and 53.2% ID/g, respectively (P = 0.009) when [(111)In]-DTPA-D-Phe1-octreotide was given 1 day after the second AdCMVhSSTr2 injection. There was no difference in [(111)In]-DTPA-D-Phe1-octreotide localization after a single AdCMVhSSTr2 injection (40.7% ID/g) or two injections of AdCMVhSSTr2 given 1 (45.9% ID/g) or 2 (53.2% ID/g) days apart, where [(111)In]-DTPA-D-Phe1-octreotide was given in each case 4 days after the first AdCMVhSSTr2 injection (P = 0.65). Therefore, two AdCMVhSSTr2 injections did not increase [(111)In]-DTPA-D-Phe1-octreotide tumor localization compared with one injection, which eliminates concerns about an immune response to a second dose of AdCMVhSSTr2. This will be the basis for a therapeutic protocol with multiple administrations of an octreotide analogue labeled with a therapeutic radioisotope. (+info)The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. (5/2596)
Tamoxifen (tam), an anti-breast cancer agent, is metabolized into tam-N-oxide by the hepatic flavin-containing monooxygenase and into N-desmethyl- and 4-hydroxy-tam by cytochrome P-450s (CYPs). Additionally, tam is metabolically activated by hepatic CYP3A, forming a reactive intermediate that binds covalently to proteins. Tam and 4-hydroxyandrostenedione (4-OH-A) are currently used to treat breast cancer, and it has been contemplated that 4-OH-A be given concurrently with tam to contravene potential tumor resistance to tam. Because alterations in tam metabolism may influence its therapeutic efficacy, the effect of 4-OH-A on tam metabolism was examined. Incubation of tam with liver microsomes from phenobarbital-treated rats, in the presence of 4-OH-A (10-100 microM), resulted in marked inhibition of tam-N-demethylation and tam covalent binding and in decreased tam-N-oxide accumulation; however, there was no inhibition of the formation of 4-hydroxy-tam and of 3,4-dihydroxytamoxifen. These findings indicate that 4-OH-A inhibits CYP3A, but not P-450(s) that catalyze tam 4-hydroxylation. The diminished tam-N-oxide accumulation could be due to decreased N-oxide formation and/or due to increased N-oxide reduction. Incubation of tam-N-oxide with liver microsomes containing heat-inactivated flavin-containing monooxygenase demonstrated that 4-OH-A increases the accumulation of tam, possibly by diminishing its P-450-mediated metabolism. Kinetic studies indicate that 4-OH-A is a competitive inhibitor of CYP3A, but not a time-dependent inactivator. Consequently, the concurrent treatment of tam and 4-OH-A may result in increased tam half-life and thus could potentiate the therapeutic efficacy of tam and diminish the potential side effects of tam by inhibiting its covalent binding to proteins and possibly to DNA. (+info)Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. (6/2596)
Tamoxifen is associated with an increased incidence of endometrial cancer in women. It is also a potent carcinogen in rat liver and forms covalent DNA adducts in this tissue. A previous study exploring DNA adducts in human endometria, utilizing thin layer chromatography 32P-postlabelling, found no evidence for adducts in tamoxifen-treated women [Carmichael,P.L., Ugwumadu,A.H.N., Neven,P., Hewer,A.J., Poon,G.K. and Phillips,D.H. (1996) Cancer Res., 56, 1475-1479]. However, subsequent work utilizing HPLC 32P-post-labelling [Hemminki,K., Ranjaniemi,H., Lindahl,B. and Moberger,B. (1996) Cancer Res., 56, 4374-4377] suggested that very low levels could be detected. We have sought to investigate this question further by reproducing the HPLC methodology at two centres, and analysing endometrial DNA from 20 patients treated with 20 mg/day tamoxifen for between 22 and 65 months. Liver DNA isolated from tamoxifen-treated rats was used as a positive control. We found no convincing evidence for tamoxifen-derived DNA adducts in human endometrium. HPLC elution profiles of post-labelled DNA from tamoxifen-treated women were indistinguishable from those obtained with DNA from 14 untreated women and from six women taking toremifene, an analogue of tamoxifen. (+info)Kleine-Levin and Munchausen syndromes in a patient with recurrent acromegaly. (7/2596)
Hypothalamic disease often affects the patients' personality and this also applies to pituitary tumors with suprasellar extension. We report on a patient with a 12-year history of recurrent acromegaly, treated with three transphenoidal operations, single field radiation therapy and bromocriptine/octreotide administration. During the course of follow-up she presented with self-inflicted anemia and Kleine-Levin syndrome (hypersomnia, hyperphagia and hypersexuality). Furthermore, she developed post-radiation necrosis within the right temporal lobe. Whether her neurological and personality disorders result - at least partially - from the acromegaly or the temporal lobe necrosis remains unclear. (+info)Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. (8/2596)
Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer, or with response to tamoxifen therapy in recurrent disease. PSA levels were determined by enzyme-linked immunosorbent assay (ELISA) in breast tumour cytosols, and were correlated with prognosis in 1516 patients with primary breast cancer and with response to first-line tamoxifen therapy in 434 patients with recurrent disease. Relating the levels of PSA with classical prognostic factors, low levels were more often found in larger tumours, tumours of older and post-menopausal patients, and in steroid hormone receptor-negative tumours. There was no significant association between the levels of PSA with grade of differentiation or the number of involved lymph nodes. In patients with primary breast cancer, PSA was not significantly related to the rate of relapse, and a positive association of PSA with an improved survival could be attributed to its relationship to age. In patients with recurrent breast cancer, a high level of PSA was significantly related to a poor response to tamoxifen therapy, and a short progression-free and overall survival after start of treatment for recurrent disease. In Cox multivariate analyses for response to therapy and for (progression-free) survival, corrected for age/menopausal status, disease-free interval, site of relapse and steroid hormone receptor status, PSA was an independent variable of poor prognosis. It is concluded that the level of PSA in cytosols of primary breast tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy. (+info)
7 Main reason whies You Should Not Rely Upon Hormonal Agent Treatment Anymore - centri
Meta-analysis Indicates Similar Outcomes With Neoadjuvant Endocrine vs Chemotherapy in Estrogen Receptor-Positive Breast Cancer...
ACOG Supports Vaginal Estrogen Use for Difficult Symptoms in Hormone-Sensitive Breast Cancer | Living Beyond Breast Cancer
You Are Going To Certainly Never Notion That Understanding Hormonal Agent Therapy May Be Thus Beneficial! | at the
5 Necessary yet little Things To Notice In Hormonal Agent Therapy | trash zom
Plus it
Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer - ONA
7 Reasons You Shouldnt Count On Hormone Therapy Anymore | showcaseing
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of...
Never Pester Hormone Treatment And also Right heres The Reasons | silc manual
endocrine treatment for breast cancer - Wholesale endocrine treatment for breast cancer
Personal Product & Services - tips on getting plane tickets at lower prices
Hormonal Agents - Pharmacology - Merck Veterinary Manual
Prosigna® FR
Prosigna® ES
Plus it
Questions to Ask Your Doctor About Hormonal Therapy | Breastcancer.org
Life Engineer and Author, Dr. G. Rex Kruhly Hosts Depth Recovery Occasion Tagged THE GENESIS OCCASION to Create Wealth,...
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive...
Recommendations for Aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive...
Hormone therapy for breast cancer | Multimedia Encyclopedia | Health Information | St. Lukes Hospital
Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines - The...
Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) - Full Text View...
Tamoxifen over the counter uk - Casa di riposo di Gandino
Five Crucial yet little Traits To Notice In Hormonal Agent Therapy - cin
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast...
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta...
Is Adjuvant Hormonal Therapy for all women with Early Breast Cancer?
Plus it
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer - Full Text View - ClinicalTrials.gov
nolva tamoxifen citrate
Adjuvant Endocrine Therapy for Breast Cancer: A Commentary | Cancer Network
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Best Anavar Online In China - Anavar for Sale
Sale Tamoxifen | Generic Tamoxifen canadian. Shaun Stewart › SunValleyOnline.com
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast...
New finding gives clues for overcoming tamoxifen-resistant breast cancer
endocrinology Archives - myCME
New HER2 Antibody-drug Conjugate; Updated APHINITY Trial Data; Addition of S-1 to Post-operative Endocrine Therapy Improves...
Uncategorized | buy essay
Plus it
How to Lower Cortisol: 17 Tips for Any Person Experiencing Anxiety and also Stress and anxiety - Follow Thoughts
Neo)Adjuvant endocrine therapy | OncologyPRO
Low-Dose Tamoxifen May Be an Option to Reduce Risk of Recurrence, Invasive Disease After Non-Invasive Breast Cancer
Tamoxifen Citrate Liquid Pct - Cost Tamoxifen Treatment
tamoxifen 10 mg --- tamoxifen for sale --- tamoxifen citrate no prescription
tamoxifen citrate square pills picture : tamoxifen citrate research chem sale : price for tamoxifen
buy tamoxifen citrate without a precription : tamoxifen citrate pills picture : cheap tamoxifen
Adjuvant Hormonal Therapy in Premenopausal Women | OncoLink
Liquid Tamoxifen Citrate - Tamoxifen And Menopause Breast Cancer
buy tamoxifen : compare tamoxifen to bso hot flashes : buy tamoxifen citrate
tamoxifen citrate pills from alinshop --- tamoxifen buy --- comprar tamoxifen en mexico
Leptin Exercise | World of Leptitox
Just what are peptides - burberryoutlet.org.uk
Women with Cancer: Im Had Enough: Half of BC Survivors Stop Tamoxifen Early
Where can i buy tamoxifen online, cheap tamoxifen online, tamoxifen online uk, buy tamoxifen online cheap
Buy Low Price Tamoxifen 20mg Online - Canadian Mail Order Tamoxifen - posted by beri at Vaal Online
JCI -
Role of steroid receptor and coregulator mutations in hormone-dependent cancers
Clinical Trial: NCT01992952 - My Cancer Genome
Buy tamoxifen uk
Im a premenopausal black woman whos been taking Tamoxifen for a little over 3 years now and have?
Dynamics of pathological factors after «test» course of preoperative endocrine therapy in menopausal patients with earlyer...
Tamoxifen | Generic Tamoxifen Online | Buy Tamoxifen | Cheap Tamoxifen
Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer | Guidance and guidelines |...
buy tamoxifen citrate --- tamoxifen price
Prednisone
"Antineoplastic Agents, Hormonal". Medical Subject Headings. U.S. National Library of Medicine. 2009. Retrieved 11 November 2010 ...
Estrogen (medication)
Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Nathanson ... "Hormonal Therapy". breastcancer.org. 26 July 2007. Retrieved 4 March 2008. Kurzer MS (2002). "Hormonal effects of soy in ... Estrogens are involved in breast development and may be used as a form of hormonal breast enhancement to increase the size of ... An estrogen (E) is a type of medication which is used most commonly in hormonal birth control and menopausal hormone therapy, ...
Bromoketoprogesterone
ISBN 978-3-642-99941-3. Alan C. Sartorelli; David G. Johns (27 November 2013). Antineoplastic and Immunosuppressive Agents. ... 185-. ISBN 978-3-642-65806-8. Goldenberg IS, Hayes MA (1959). "Hormonal therapy of metastatic female breast carcinoma. I. 9 ... Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. Halogenated ... Tyler, Edward T. (1959). "Fertility promoting and inhibiting effects of new steroid hormonal substances". Journal of the ...
Cytestrol acetate
List of hormonal cytostatic antineoplastic agents Oborotov, A. V.; Smirnova, Z. S.; Osetrova, I. P.; Polozkova, A. P.; ... Cytestrol acetate is a steroidal antiestrogen and a cytostatic antineoplastic agent (i.e., chemotherapeutic) which was ...
Alestramustine
List of hormonal cytostatic antineoplastic agents List of estrogen esters § Estradiol esters NCI Thesaurus. "Alestramustine". ... Milne GW (1 July 2000). Ashgate Handbook of Antineoplastic Agents. Wiley. p. 5. ISBN 978-0-566-08382-2. Tripathi KD (30 ... is a cytostatic antineoplastic agent which was never marketed. It is the L-alanine ester of estramustine, which is a ...
ICI-85966
List of hormonal cytostatic antineoplastic agents List of estrogen esters J. Elks (14 November 2014). The Dictionary of Drugs: ... nonsteroidal estrogen and cytostatic antineoplastic agent of the stilbestrol group and a nitrogen mustard ester of ...
Prednimustine
List of hormonal cytostatic antineoplastic agents List of corticosteroid esters J. Elks (14 November 2014). The Dictionary of ... 868-. ISBN 978-3-88763-075-1. I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: ...
Phenestrol
List of hormonal cytostatic antineoplastic agents List of estrogen esters J. Elks (14 November 2014). The Dictionary of Drugs: ... nonsteroidal estrogen and cytostatic antineoplastic agent (i.e., chemotherapy drug) and a chlorphenacyl nitrogen mustard ester ... Lagova ND, Sof'ina ZP, Shkodinskaia EN, Kurdiumova KN, Valueva IM (1988). "[The antineoplastic activity of testiphenon]". Vopr ...
Estramustine
List of hormonal cytostatic antineoplastic agents List of estrogen esters § Estradiol esters Elks J (14 November 2014). The ... Estramustine (INN, USAN, BAN) is an estrogen and cytostatic antineoplastic agent which was never marketed. It is an estrogen ...
Estradiol mustard
List of hormonal cytostatic antineoplastic agents List of estrogen esters § Estradiol esters J. Elks (14 November 2014). The ... steroidal estrogen and cytostatic antineoplastic agent and a chlorphenacyl nitrogen mustard-coupled estrogen ester that was ... 898-. ISBN 978-1-4757-2085-3. Asai M, Takeuchi H, Okada H (1978). "In vivo interaction between steroidal alkylating agents and ... V. H. T. James; J. R. Pasqualini (22 October 2013). Hormonal Steroids: Proceedings of the Sixth International Congress on ...
Atrimustine
List of hormonal cytostatic antineoplastic agents List of estrogen esters § Estradiol esters J. Elks (14 November 2014). The ... is a cytostatic antineoplastic agent which was under development in Japan by Kureha Chemicals (now Kureha Corporation) for the ... Ohsawa N, Yamazaki Z, Wagatsuma T, Isurugi K (1984). "[Bestrabacil: a possible target-oriented anticancer agent]". Gan to ...
Estromustine
List of hormonal cytostatic antineoplastic agents List of estrogen esters § Estradiol esters Chabner BA, Longo DL (7 December ... is a major active metabolite of the cystotatic antineoplastic agent and estrogen estramustine phosphate, a medication used in ...
Cortifen
List of hormonal cytostatic antineoplastic agents List of corticosteroid esters Lagova ND, Kiselev VI, Kurdiumova KN, Sof'ina ... is a synthetic glucocorticoid corticosteroid and cytostatic antineoplastic agent which was developed in Russia for potential ... V.; Khalanskii, A. S.; Gershtein, E. S.; Gerasimova, G. K. (1999). "Dependence of antitumor effect of hormonal cytostatic ...
Androstanolone
"In Sartorelli AC, Johns DJ (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170-192. doi:10.1007/978-3-642-65806-8_11. ... Segaloff A, Horwitt BN, Cakabasi RA, Murison PJ, Osser JV (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of ... Morton I, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & ... However, androstanolone is nonetheless described as a very poor anabolic agent.[35] This is attributed to its high affinity as ...
Testifenon
List of hormonal cytostatic antineoplastic agents List of androgen esters § Dihydrotestosterone esters Lagova ND, Sof'ina ZP, ... and a cytostatic antineoplastic agent (i.e., chemotherapeutic) that was never marketed. It is an androgen ester - specifically ... Shkodinskaia EN, Kurdiumova KN, Valueva IM (1988). "[The antineoplastic activity of testiphenon]". Vopr Onkol (in Russian). 34 ...
Cancer
Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents) as part of a ... The primary ones include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and palliative care. ... Hormones are important agents in sex-related cancers, such as cancer of the breast, endometrium, prostate, ovary and testis and ... Traditional chemotherapeutic agents act by killing cells that divide rapidly, a critical property of most cancer cells. It was ...
N-Desmethylenzalutamide
... an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer. It has similar ...
LS-1727
... which was developed as a cytostatic antineoplastic agent but was never marketed. List of hormonal cytostatic antineoplastic ... nitrosocarbamates as potential anticancer agents". J. Med. Chem. 43 (8): 1484-8. doi:10.1021/jm990417j. PMID 10780904. J. Elks ... agents List of androgen esters § Nandrolone esters Reynolds RC, Tiwari A, Harwell JE, Gordon DG, Garrett BD, Gilbert KS, Schmid ...
5α-Dihydroethisterone
... used but now-discontinued progestin ethisterone and the experimental and never-marketed hormonal antineoplastic agent ...
ERX-11
... is a novel antiestrogen and experimental hormonal antineoplastic agent which is being researched for the potential treatment of ... Ekoue DN, Unni N, Raj GV (April 2018). "A new class of agents for estrogen-receptor-positive breast cancer". Expert Rev Clin ...
Hormonal therapy (oncology)
List of hormonal cytostatic antineoplastic agents Antiestrogen withdrawal response DeVita, Vincent T.; Hellman, Samuel; ... Selective estrogen receptor modulators (SERMs) are an important class of hormonal therapy agents which act as antagonists of ... although another class of hormonal agents, aromatase inhibitors, now have an expanding role in that disease. One effective ... Hormonal therapy in oncology is hormone therapy for cancer and is one of the major modalities of medical oncology ( ...
List of sex-hormonal aqueous suspensions
Antineoplastic and Immunosuppressive Agents. Springer Science & Business Media. pp. 181-. ISBN 978-3-642-65806-8. Heinrich Kahr ... This is a list of known sex-hormonal crystalline aqueous suspension formulations. Brand names and developmental code names are ... "Long-acting hormonal contraceptives for women". J. Steroid Biochem. Mol. Biol. 40 (4-6): 697-704. doi:10.1016/0960-0760(91) ... List of combined sex-hormonal preparations List of androgen esters List of estrogen esters List of progestogen esters Alan C. ...
List of hormonal cytostatic antineoplastic agents
This is a list of dual hormonal and cytostatic antineoplastic agents. Estramustine phosphate (Emcyt, Estracyt; Leo 299, NSC- ...
Estradiol
Sartorelli AC, Johns DG (27 November 2013). Antineoplastic and Immunosuppressive Agents. Springer Science & Business Media. pp ... Gruhn JG, Kazer RR (11 November 2013). Hormonal Regulation of the Menstrual Cycle: The Evolution of Concepts. Springer Science ... "Hormonal modulation of singing: hormonal modulation of the songbird brain and singing behavior". Annals of the New York ...
Estrogen ester
... as well as the nitrogen mustard alkylating antineoplastic agent estramustine phosphate (estradiol normustine phosphate). The ... Estrogen esters are used in hormone therapy, hormonal contraception, and high-dose estrogen therapy (e.g., for prostate cancer ...
Megestrol acetate
MGA is also used as an antineoplastic agent in the treatment of breast cancer and endometrial cancer. It is significantly ... Gordon D, Horwitt BN, Segaloff A, Murison PJ, Schlosser JV (March 1952). "Hormonal therapy in cancer of the breast. III. Effect ... 554-. ISBN 978-3-642-96158-8. Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, ... Maltry, E. (1970). Use of megestrol acetate (a new progestational agent) in the treatment of carcinoma of the prostate. In ...
High-dose estrogen
... danazol became the primary hormonal agent used in the treatment of endometriosis. In the 1990s the GnRH agonists have become ... an estradiol ester that is also a cytostatic antineoplastic agent; used for prostate cancer only) Ethinylestradiol, its ether ... Pseudopregnancy simulates the hormonal profile of the first trimester of pregnancy. HDE has been used since the discovery and ... In the early 1950s the high-dose estrogen regimen of Karnaky was the only available hormonal treatment for endometriosis. In ...
List of MeSH codes (D27)
... antineoplastic agents, alkylating MeSH D27.505.954.248.169 - antineoplastic agents, hormonal MeSH D27.505.954.248.179 - ... MeSH D27.505.519.124 - alkylating agents MeSH D27.505.519.124.035 - antineoplastic agents, alkylating MeSH D27.505.519.155 - ... lipotropic agents MeSH D27.505.954.248 - antineoplastic agents MeSH D27.505.954.248.025 - angiogenesis inhibitors MeSH D27.505. ... alkylating agents MeSH D27.888.569.035.035 - antineoplastic agents, alkylating MeSH D27.888.569.042 - antimetabolites MeSH ...
Estramustine phosphate
EMP is a dual cytostatic and hence chemotherapeutic agent and a hormonal anticancer agent of the estrogen type. It is a prodrug ... Antineoplastic agents related to EMP, although none of them were marketed, include alestramustine, atrimustine, cytestrol ... EMP is described as relatively well tolerated among cytostatic antineoplastic and nitrogen-mustard agents, rarely or not at all ... and hence was thought to be an alkylating antineoplastic agent. However, subsequent research has found that EMP is devoid of ...
Acolbifene
List of investigational hormonal agents § Estrogenics. References[edit]. *^ Gauthier, S; Cloutier, J; Dory, YL; Favre, A; ... This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.. *v ...
Gonadotropin-releasing hormone agonist
The agents nafarelin and triptorelin are agonists with single substitutions at position 6. ... Hormonal antineoplastic drugs. *Gonadotropin-releasing hormone and gonadotropins. *Progonadotropins. Navigation menu. Personal ... Cryptorchidism; Delayed puberty; Diagnostic agent (pituitary disorders); Hypogonadotropic hypogonadism; Veterinary medicine ( ... endometrial thinning agent); Uterine fibroids; Uterine hemorrhage. Implant. 1989. 400,000 ...
Antiemetic
Cannabinoids are used in patients with cachexia, cytotoxic nausea, and vomiting, or who are unresponsive to other agents. These ...
Analgesic
Psychotropic agents[edit]. Other psychotropic analgesic agents include ketamine (an NMDA receptor antagonist), clonidine and ... Unselective agents Aceclofenac. Comes in betadex salt and free acid forms; practically insoluble in water, soluble in many ... Other agents directly potentiate the effects of analgesics, such as using hydroxyzine, promethazine, carisoprodol, or ... When choosing analgesics, the severity and response to other medication determines the choice of agent; the World Health ...
Stimulant
It may be used as a nasal/sinus decongestant, as a stimulant,[119] or as a wakefulness-promoting agent.[120] ... Tashkin, D. P. (1 March 2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents". Current Opinion in ... and anorectic agent.[112] It is commonly used in prescription and over-the-counter cough and cold preparations. In veterinary ... "Phenylisopropylamine stimulants: amphetamine-related agents". In Lemke TL, Williams DA, Roche VF, Zito W (eds.). Foye's ...
Chemotherapy
Available agents[edit]. Main article: List of antineoplastic agents. There is an extensive list of antineoplastic agents. ... possible roles for hormonal and non-hormonal attenuating agents". Human Reproduction Update. 20 (5): 759-774. PMID 24833728. ... Alkylating agents[edit]. Main article: Alkylating antineoplastic agent. Alkylating agents are the oldest group of ... The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs.[ ...
Decongestant
List of agents[edit]. Adrenaline releasing agents[edit]. Main article: Norepinephrine releasing agent ... 3 List of agents *3.1 Adrenaline releasing agents *3.1.1 Common or widely marketed ... since these agents lose effectiveness after a few days. ... Hormonal contraception. *Fertility agents. *SERMs. *Sex ...
Cancer
Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents) as part of a ... The primary ones include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and palliative care. ... Hormones are important agents in sex-related cancers, such as cancer of the breast, endometrium, prostate, ovary and testis and ... Physical agents. Some substances cause cancer primarily through their physical, rather than chemical, effects.[63] A prominent ...
Antifungal
"Dermatotherapeutic Agents". Ullmann's Encyclopedia of Industrial Chemistry (7th ed.). 2007. doi:10.1002/14356007.a08_301.pub2. ... Kyriakidis I, Tragiannidis A, Munchen S, Groll AH (February 2017). "Clinical hepatotoxicity associated with antifungal agents ... "The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents ... "Current and emerging azole antifungal agents". Clinical Microbiology Reviews. 12 (1): 40-79. PMC 88906. PMID 9880474 ...
WHO Model List of Essential Medicines
8 Immunomodulators and antineoplastics *8.1 Immunomodulators for non-malignant disease. *8.2 Antineoplastics and supportive ... Lipid-lowering agents[edit]. *Simvastatin[note 72]. Dermatological medicines (topical)[edit]. Antifungal medicines[edit]. * ... Injectable hormonal contraceptives[edit]. *Estradiol cypionate/medroxyprogesterone acetate. *Medroxyprogesterone acetate. * ... Immunomodulators and antineoplastics[edit]. Immunomodulators for non-malignant disease[edit]. *Adalimumabα[note 59] ...
Proton-pump inhibitor
Within the class of medications, there is no clear evidence that one agent works better than another.[1][2] ... In British Columbia, Canada the cost of the PPIs varies significantly from 0.20 CAD to 2.38 CAD per dose while all agents in ... The cost between different agents varies significantly.[1] ... Hormonal contraception. *Fertility agents. *SERMs. *Sex ...
Diuretic
The term "calcium-sparing diuretic" is sometimes used to identify agents that result in a relatively low rate of excretion of ... Alternatively, an antidiuretic, such as vasopressin (antidiuretic hormone), is an agent or drug which reduces the excretion of ... Diuretics increase the urine volume and dilute doping agents and their metabolites. Another use is to rapidly lose weight to ... "The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and ...
Prednisone
"Antineoplastic Agents, Hormonal". Medical Subject Headings. U.S. National Library of Medicine. 2009. Retrieved 11 November 2010 ...
Local anesthetic
Reducing agent (antioxidant), e.g. if epinephrine is used, then sodium metabisulfite is used as a reducing agent ... LA drugs are also often combined with other agents such as opioids for synergistic analgesic action.[1] Low doses of LA drugs ... This can be a factor in choosing an agent in patients with liver failure,[56] although since cholinesterases are produced in ... Even with proper administration, it is inevitable for some diffusion of agent into the body from the site of application due to ...
Medication
antifungal, alkalinizing agents, quinolones, antibiotics, cholinergics, anticholinergics, antispasmodics, 5-alpha reductase ... Hormonal contraception. *Ormeloxifene. *Spermicide. For obstetrics and gynecology[edit]. NSAIDs, anticholinergics, haemostatic ... In the inter-war period, the first anti-bacterial agents such as the sulpha antibiotics were developed. The Second World War ... These were drugs that worked chiefly as anti-anxiety agents and muscle relaxants. The first benzodiazepine was Librium. Three ...
Immunosuppressive drug
Alkylating agents[edit]. The alkylating agents used in immunotherapy are nitrogen mustards (cyclophosphamide), nitrosoureas, ... Small biological agents[edit]. Fingolimod is a new synthetic immunosuppressant, currently in phase 3 of clinical trials. It ... Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications are drugs ... Immunosuppressive+Agents at the US National Library of Medicine Medical Subject Headings (MeSH) ...
Immunosuppressive drug
Alkylating agents[edit]. The alkylating agents used in immunotherapy are nitrogen mustards (cyclophosphamide), nitrosoureas, ... Small biological agents[edit]. Fingolimod is a new synthetic immunosuppressant, currently in phase 3 of clinical trials. It ... Immunosuppressive drugs or immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of ... Immunosuppressive+Agents at the US National Library of Medicine Medical Subject Headings (MeSH) ...
Antiestrogen
Hormonal antineoplastic drugs. *Progonadotropins. *Transgender and medicine. Hidden categories: *Commons category link is on ... is often reserved for agents reducing the response to estrogen.[7] ...
Dissociative
Agents Chemother. 12 (5): 642-6. doi:10.1128/AAC.12.5.642. PMC 429991 . PMID 303498.. ... Also indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, ... Virtue, RW; Alanis, JM; Mori, M; Lafargue, RT; Vogel, JH; Metcalf, DR (1967). "An anaesthetic agent: 2-orthochlorophenyl, 2- ... a PCP-receptor-acylating agent". Synapse. 1 (5): 497-504. doi:10.1002/syn.890010514. PMID 2850626.. ...
Bronchodilator
"Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review" (PDF). Respiratory Care. 60 ...
Polyestradiol phosphate
This newer parenteral estrogen application shows encouraging results of a cheap and effective hormonal therapy with a low rate ... it very slowly releases the active agent estradiol over at least several months.[20][7] ... PEP has been studied as a means of hormonal breast enhancement in women.[66] ... Hartmann BW, Laml T, Kirchengast S, Albrecht AE, Huber JC (1998). "Hormonal breast augmentation: prognostic relevance of ...
High-dose estrogen
Estramustine phosphate (an estradiol ester that is also a cytostatic antineoplastic agent; used for prostate cancer only) ... danazol became the primary hormonal agent used in the treatment of endometriosis. In the 1990s the GnRH agonists have become ... Hormonal therapy. During the past 40 years, the medical management of endometriosis has become significantly more sophisticated ... Pseudopregnancy simulates the hormonal profile of the first trimester of pregnancy.[45] ...
Depressant
Hormonal contraception. *Fertility agents. *SERMs. *Sex hormones. Endocrine. system (H). *Hypothalamic-pituitary hormones ...
Statin
LDL-lowering potency varies between agents. Cerivastatin is the most potent, (withdrawn from the market in August, 2001 due to ... Thurnher M, Nussbaumer O, Gruenbacher G (July 2012). "Novel aspects of mevalonate pathway inhibitors as antitumor agents". ... The first agent they identified was mevastatin (ML-236B), a molecule produced by the fungus Penicillium citrinum. ... Several combination preparations of a statin and another agent, such as ezetimibe/simvastatin, are also available. In 2005, ...
Muscle relaxant
... "centrally acting agents",[10] but adds a distinct category of "directly acting agents", for dantrolene.[11] Use of this ... Several of these agents also have abuse potential, and their prescription is strictly controlled.[22][23][24] ... However, it is now known not every agent in this class has CNS activity (e.g. dantrolene), so this name is inaccurate.[5] ... "M03B Muscle Relaxants, Centrally acting agents". ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.. ...
Stimulant
It may be used as a nasal/sinus decongestant, as a stimulant,[116] or as a wakefulness-promoting agent.[117] ... Tashkin, D. P. (1 March 2001). "Airway effects of marijuana, cocaine, and other inhaled illicit agents". Current Opinion in ... Amphetamine is a norepinephrine-dopamine releasing agent (NDRA). It enters neurons through dopamine and norepinephrine ... and anorectic agent.[109] It is commonly used in prescription and over-the-counter cough and cold preparations. In veterinary ...
Drostanolone propionate
I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer ... Hormonal treatment is part of the complex therapy for some kind of tumors, particularly the ones associated with hormone-active ... Hormonal antineoplastic drugs. *Ketones. *Prodrugs. *Propionates. *World Anti-Doping Agency prohibited substances ...
Pharmacology
This network is made up of protein-protein interactions from Treponema pallidum, the causative agent of syphilis and other ... Targets in synapses can be modulated with pharmacological agents. In this case, cholinergics (such as muscarine) and ...
Antineoplastic Agents, Hormonal - DrugBank
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, ... For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in ... Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic ... A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone- ...
List of hormonal cytostatic antineoplastic agents - Wikipedia
Antineoplastic Agents, Hormonal | DrugBank Online
Antineoplastic Agents, Hormonal. Accession Number. DBCAT000063. Description. Antineoplastic agents that are used to treat ... A synthetic estrogen that has been used as a hormonal antineoplastic agent. ... An antineoplastic agent used for the management of metastatic and/or progressive prostate cancer in palliative setting. ... orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat ...
Antineoplastic Agents, Hormonal | Profiles RNS
"Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major ... Antineoplastic Agents, Hormonal*Antineoplastic Agents, Hormonal. *Hormonal Agents, Antineoplastic. *Hormonal Antineoplastic ... "Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ( ... Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles. ...
Dromostanolone
-
Anabolic Agents, Antineoplastic Agents, Hormonal
Dromostanolone is a synthetic androgen, or male hormone, similar to testosterone. Dromostanolone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells ...
Prednisone - Wikipedia
Hormonal agents, Ethers, Dermatologic drugs, Hormonal antineoplastic drugs
-
Chemical Safety, Models, Suppliers,...
Hormonal agents, Ethers, Aromatic compounds, Antineoplastic and immunomodulating drugs
-
Chemical Safety, Models,...
Anti - Neoplastic Agents Market Emerging Trends || Leading
Neoplastic Agents Market Emerging Trends ,, Leading Players are Roche, Novartis, Celgene - published on openPR.com ... This study provides Anti - Neoplastic Agents sales, revenue, and market share for each player covered in this report for a ... Hormonal Therapy (Biologic Therapy). Others. By Applications:. Blood Cancer. Breast Cancer. Gastrointestinal Cancer. Prostate ... The Anti - Neoplastic Agents Market report provides a detailed analysis of the global market size, regional and country-level ...
Male Infertility Related With Post Infection Inflammatory Syndrome - Full Text View - ClinicalTrials.gov
Neo-adjuvant Abiraterone Prostate Study - Full Text View - ClinicalTrials.gov
Antineoplastic Agents, Hormonal. Antineoplastic Agents. Steroid Synthesis Inhibitors. Enzyme Inhibitors. Molecular Mechanisms ... Experimental: Combined hormonal therapy Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days ... Anti-Inflammatory Agents. Glucocorticoids. Hormones. Hormones, Hormone Substitutes, and Hormone Antagonists. Physiological ... Prior treatment for prostate carcinoma, including prostatectomy; high intensity focused ultrasound or cryotherapy; hormonal ...
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer - Full Text View -...
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer - Full Text View - ClinicalTrials.gov
Antineoplastic Agents, Hormonal. Antineoplastic Agents. Androgen Antagonists. Hormone Antagonists. Hormones, Hormone ... and prior hormonal therapy (neoadjuvant hormonal therapy vs finasteride vs neither). ... More than 1 year since any prior neoadjuvant or adjuvant hormonal therapy for a duration of no more than 4 months ...
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer - Full Text...
Antineoplastic Agents, Alkylating. Alkylating Agents. Molecular Mechanisms of Pharmacological Action. Antineoplastic Agents. ... Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, ... Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. Antirheumatic Agents. ...
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research...
Medication Appropriateness in Prehospital Care
Stimulus-Responsive Polymeric Nanogels as Smart Drug Delivery Systems.
Antineoplastic Agents, Hormonal. Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive ... If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the ... A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone- ... particles under 100 nanometers possessing many biomedical applications including DRUG DELIVERY SYSTEMS and CONTRAST AGENTS. The ...
CYP2C19 | Cancer Genetics Web
Antineoplastic Agents, Hormonal. *Stereoisomerism. *Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. *Genotype ... Adjuvant endocrine therapy as well as other forms of targeted therapy such as HER2 inhibitors and antiangiogenic agents reduce ... Significant association of CYP2B6 transcript levels in tumors with expression of hormonal receptors was found in the ... our findings provide an immediate cue for clinical studies to evaluate the utility of PPARα ligands as safe agents for the ...
ACSL3 | Cancer Genetics Web
Antineoplastic Agents, Hormonal. *Gene Expression Profiling. *FISH. *Cohort Studies. *RTPCR. *long-chain-fatty-acid-CoA ligase ... The aim of the present study was to characterize the androgen receptor (AR) response in hormonal therapy-resistant PC346 cells ... In (early) prostate cancer (PCa) androgens also regulate tumor growth, which is exploited by hormonal therapies in metastatic ... Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.. PLoS One. 2011; 6(8): ...
Utilização de recursos no tratamento do câncer de mama avançado de pacientes pós...
Antineoplastic agents hormonal. Breast neoplasm. Costs and cost analysis. Fulvestrant. Neoplasm metastasis. ... Antineoplásicos hormonal. Custos e análise de custos. Fulvestranto. Metástase neoplásica. Neoplasias da mama. ... Only patients without visceral crisis and with at least one previous hormonal therapy were considered eligible. Medical charts ... Apenas pacientes sem crise visceral e com pelo menos uma terapia anterior hormonal foram considerados elegÃveis. Os prontuários ...
Prostate Cancer Medication: Antineoplastics, GnRH Agonist, Antineoplastics, Antiandrogen, Antineoplastics, Antimicrotubular,...
Antineoplastics, Hormones. Class Summary. Estramustine is a conjugate of an alkylating agent to estradiol. As a single agent, ... Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an ... Antineoplastics, Antimicrotubular. Class Summary. Antimicrotubule chemotherapy agents such as docetaxel and cabazitaxel have ... Antifungal agents such as ketoconazole produce a response similar to that of antiandrogens. These agents provide an alternative ...
Drug Information Portal - U.S. National Library of Medicine - Quick Access to Quality Drug Information
Pulmonary lymphangioleiomyomatosis in Korea.
Antineoplastic Agents, Hormonal / therapeutic use. Female. Humans. Korea. Lung / pathology, physiopathology, radiography. Lung ... CONCLUSIONS: As in other countries, in Korea LAM occurs exclusively in women and progresses despite hormonal treatment.. ... 0/Antineoplastic Agents, Hormonal; 10540-29-1/Tamoxifen; 520-85-4/Medroxyprogesterone ...
Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for...
MEDLINE - Resultado p gina 1
Taxfeno (Tamoxifen) Raffo Laboratorios
Hormonal Agents - Pharmacology - Merck Veterinary Manual
Learn about the veterinary topic of Hormonal Agents. Find specific details on this topic and related topics from the Merck Vet ... of certain lymphomas with prednisone may increase resistance of neoplastic cells to subsequent cycles of antineoplastic ... Hormonal Agents By Lisa G. Barber, DVM, Assistant Professor, Cummings School of Veterinary Medicine, Tufts University ; ... Hormonal therapy for neoplasia commonly involves use of glucocorticoids. Direct antitumor effects are related to their ...
Anastrozole (Anastrozole) Kudco Ireland
Pexidartinib and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed...
Concomitant treatment with other anti-neoplastic agents (hormonal therapy acceptable). *Patients with symptomatic brain ... For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method ... Pregnant women are excluded from this study because pexidartinib (PLX3397) and Sirolimus are agents with the potential for ... Patients who are receiving any other investigational agents concurrently. * ...
PharmacologyAromatase InhibitorsPotential antineoplastic activityImmunotherapyTherapyTherapeuticDrugsPreparationsSystemicAntibioticsTherapiesMeSHHormonesTamoxifenBreastIMMUNOMODULATING AGENTSMETABOLISMStructurallyAnthracyclineProstate cancerTumor cellsAntitumorProtocolsNeoplastic cellsMedicationContraceptiveChemotherapeuticMetastaticTreatmentChemicalAntigenPaclitaxelExperimentalSyntheticClinical TrialsOralDrugPharmacological
Pharmacology2
- Discuss the pharmacology including mechanism of action, adverse reactions, dose ranges, and pharmacokinetics of the common cancer chemotherapeutic agents, hormonal and immunotherapeutic agents, and monitor their use in patients with cancer. (arizona.edu)
- The in vitro screening of a broad range of drugs already approved for other indications is attractive as in vivo toxicity and pharmacology are well defined, and such compounds can enter GBM clinical trials rapidly either as single agents or as combinations. (biomedcentral.com)
Aromatase Inhibitors1
- This review found that anastrozole was more effective than tamoxifen in adjuvant hormonal treatment of early breast cancer in postmenopausal women, and that aromatase inhibitors should be the initial hormone therapy for its treatment. (york.ac.uk)
Potential antineoplastic activity7
- One way to go forward is to draw lessons from ancient ethnopharmacological wisdom and to evaluate the plant biodiversity for compounds with potential antineoplastic activity. (intechopen.com)
- R-(-)-gossypol acetic acid - The orally bioavailable solvate of the R-(-) enantiomer of gossypol and acetic acid with potential antineoplastic activity. (wikimd.org)
- Racemetyrosine/methoxsalen/phenytoin/sirolimus sm-88 - A combination agent containing racemetyrosine, methoxsalen, phenytoin and sirolimus, with potential antineoplastic activity. (wikimd.org)
- Radgocitabine - An analogue of the nucleoside deoxycytidine with potential antineoplastic activity. (wikimd.org)
- Nab-paclitaxel/rituximab-coated nanoparticle ar160 - A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. (wikimd.org)
- Nadofaragene firadenovec - A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. (wikimd.org)
- Nadofaragene firadenovec/syn3 - A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN alpha-2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. (wikimd.org)
Immunotherapy3
- The most recent research has been in the field of immunotherapy and how agents that act on the immune system can be used to manage prostate cancer. (uspharmacist.com)
- The remainder of this article focuses largely on the few immunotherapy agents that have shown promising results in patients with mCRPC. (uspharmacist.com)
- Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others.The global Anti - Neoplastic Agents market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. (amarketforecast.com)
Therapy17
- The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy. (clinicaltrials.gov)
- Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy Alone Vs Three Dimensional Conformal Therapy / Intensity Modulated Radiotherapy Plus Adjuvant Hormonal Therapy In Localized T1b-c, T2a, N0, M0 Prostatic Carcinoma. (clinicaltrials.gov)
- Patients are stratified according to SWOG performance status (0-1 vs 2), severity of disease (minimal vs extensive), and prior hormonal therapy (neoadjuvant hormonal therapy vs finasteride vs neither). (clinicaltrials.gov)
- OBJECTIVES: To estimate the resource utilization and costs related to endocrine therapy (ET) versus chemotherapy (CT) in the treatment of hormonal receptor positive (HR+), advanced breast cancer (ABC) patients, after at least one previous ET. (usp.br)
- Only patients without visceral crisis and with at least one previous hormonal therapy were considered eligible. (usp.br)
- Hormonal therapy for neoplasia commonly involves use of glucocorticoids. (merckvetmanual.com)
- By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. (nih.gov)
- Moreover, miR-100 favors BrCSC differentiation, converting a basal like phenotype into luminal.It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy.Our findings indicate a new possible therapeutic strategy, which could make aggressive breast cancers responsive to standard treatments. (nih.gov)
- It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy. (nih.gov)
- Several surveys have shown that most patients prefer oral antineoplastic drugs to intravenous treatment primarily for the convenience of a home-based therapy and ease of use [ 2 , 3 ]. (hindawi.com)
- After platinum and paclitaxel, topotecan is the agent that has undergone the most extensive testing to define a role as second-line therapy for recurrent ovarian cancer [19, 20], and has been approved by the U.S. Food and Drug Administration (FDA) for that indication. (dailystrength.org)
- At this point, single-agent therapy remains the most appropriate option for patients with recurrent disease. (dailystrength.org)
- Doxorubicin in known to be an active agent in ovarian cancer, and has been evaluated in front-line therapy with cisplatin and cyclophosphamide, achieving a small impact on long-term survival that was detectable in a meta-analysis of randomized trials prior to the advent of paclitaxel [24]. (dailystrength.org)
- This study evaluated an algorithm in which endoxifen levels and CYP2D6 genotypes were used to make hormonal therapy recommendations for patients on adjuvant tamoxifen for breast cancer. (elsevier.com)
- 12 Medical hormonal therapy traditionally involves the use of luteinizing hormone-releasing hormone (LH-RH) agonists or antiandrogens given alone or in combination. (uspharmacist.com)
- General Function Oxidoreductase activity, and incorporation of nolvadex d 20mg atom of oxygen Specific Function Cytochromes P nolvadex d 20mg a group nolvadex d 20mg heme-thiolate monooxygenases, and I try to use very carefully and wisely, some of which may be serious and could include cancer, seldom resulting in withdrawal of therapy with the hormonal antineoplastic agent. (thedomains.com)
- Corticosteroids are used in clinically for hormonal replacement therapy, for suppression of ACTH, as antineoplastic, antiallergic, and anti-inflammatory agents, and to suppress immune responses. (chemicalland21.com)
Therapeutic2
- Oral chemotherapy agents have regimens that have novel toxicity profiles and require strict adherence for optimal therapeutic effects, frequent monitoring of laboratory parameters, monitoring for drug interactions, and proper handling and disposal methods. (uspharmacist.com)
- BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid (clinical formulation BXQ-350). (clinicalconnection.com)
Drugs10
- The drugs Infliximab and Anti-Bacterial Agents have been mentioned in the context of this disorder. (malacards.org)
- The existence of rare but exceptional results with immunomodulators in metastatic patients triggered initiation of trials testing these drugs, combined or not with antineoplastic agents in the adjuvant setting. (biomedcentral.com)
- Despite much progress in our understanding of the essence of cancer, remarkable advances in methods for early diagnosis, the expanding array of antineoplastic drugs and treatment modalities, as well as important refinements in their use, this disease is among the leading causes of morbidity and mortality in many parts of the world. (intechopen.com)
- Currently, there are more than sixty oral antineoplastic drugs available, 22 of which are oral kinase inhibitors that have gained worldwide approval since 2001 [ 1 ]. (hindawi.com)
- Experts now estimate that more than one-quarter of the 400 antineoplastic agents now under development are planned as oral drugs [ 2 - 4 ]. (hindawi.com)
- To ensure effectiveness of these agents while maintaining patient safety, pharmacists need to be familiar with the drugs employed. (uspharmacist.com)
- Potential drugs being explored are either hormonally-based and impede the production of sperm, or they are non-hormonal and render the sperm dysfunctional. (usc.edu)
- So far, developmental efforts have focused in two realms: hormonal and non-hormonal drugs. (usc.edu)
- Human cytochrome P450 3A4 (P450 3A4) is one of the most abundant xenobiotic-metabolizing enzymes in the human liver ( 1 ) and intestine ( 2 , 3 ) and is capable of oxidizing a wide range of structurally diverse drugs, including antineoplastic, antihistaminic, cardiac, psychotropic, analgesic, hormonal, and immunosuppresant agents ( 4 ). (pnas.org)
- Screens using human GBM cell lines revealed 22 drugs with potent anti-GBM activity, including serotonergic blockers, cholesterol-lowering agents (statins), antineoplastics, anti-infective, anti-inflammatories, and hormonal modulators. (biomedcentral.com)
Preparations1
- Other hormones, see H - Systemic hormonal preparations, excl. (whocc.no)
Systemic1
- Growth Failure in Children with Systemic Juvenile Idiopathic Arthritis and Prolonged Inflammation despite Treatment with Biologicals: Late Normalization of Height by Combined Hormonal Therapies. (bioportfolio.com)
Antibiotics2
- The antineoplastic antibiotics are products of Streptomyces . (merckvetmanual.com)
- The anthracycline antibiotics, particularly doxorubicin , have become important antineoplastic antibiotics. (merckvetmanual.com)
Therapies2
- The heterogeneous adverse effects induced by antineoplastic agents (cytotoxic and novel anticancer agents, tyrosine kinase inhibitors, bexarotene- and iodine-based cancer therapies, and radioimmunotherapies) will be highlighted. (springer.com)
- Hormonal therapies are not included. (jointcommission.org)
MeSH1
- Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
Hormones2
- Sex hormones used only in the treatment of cancer (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents. (whocc.no)
- The hormonal solution, as its name implies, uses various hormones to stop or significantly reduce spermatogenesis and has been proven successful in many different studies worldwide. (usc.edu)
Tamoxifen2
- Anastrozole appeared to be more effective than tamoxifen in the adjuvant hormonal treatment of early breast cancer. (york.ac.uk)
- Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments. (elsevier.com)
Breast4
- To be eligible, studies needed to be randomised controlled trials (RCTs) that compared anastrozole with another agent in the adjuvant treatment of early breast cancer. (york.ac.uk)
- The hormonal dependencies of endometrial as well as breast cancers suggest that this difference may be attributed to the hormonal diversities of the pre- and postmenopausal hormonal milieu. (aacrjournals.org)
- This medication is an oral antineoplastic agent, prescribed for cutaneous T-cell lymphoma (CTCL, a type of skin cancer), lung cancer, breast cancer and Kaposi's sarcoma. (medindia.net)
- Testolactone , or Teslac (brand name) is an antineoplastic agent that is a derivative of progesterone and is used to treat advanced stage breast cancer . (wikidoc.org)
IMMUNOMODULATING AGENTS1
- Progestogens only used in neoplastic diseases, see L - Antineoplastic and immunomodulating agents. (whocc.no)
METABOLISM1
- Our results define a dietary manipulation that can enhance the efficacy of biguanides as antineoplastic agents that target cancer cell energy metabolism. (aacrjournals.org)
Structurally2
- Testolactone is a synthetic antineoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. (wikidoc.org)
- Here, we show that serine withdrawal increases the antineoplastic effects of phenformin (a potent biguanide structurally related to metformin). (aacrjournals.org)
Anthracycline1
- N,n-dibenzyl daunomycin - The N-alkylated analogue of the anthracycline antineoplastic antibiotic daunomycin. (wikimd.org)
Prostate cancer6
- Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer. (drugbank.ca)
- An antineoplastic agent used for the management of metastatic and/or progressive prostate cancer in palliative setting. (drugbank.com)
- Casodex 50 mg Tablet is a non-steroidal anti-cancer medicine used in men along with other specific agents for the treatment of prostate cancer. (practo.com)
- A range of agents and techniques are currently employed in the management of prostate cancer. (uspharmacist.com)
- Eventually, the disease progresses further, resulting in castration-resistant prostate cancer, which typically requires the use of IV antineoplastic agents to extend overall survival, mitigate pain associated with the disease, and improve quality of life. (uspharmacist.com)
- This medication is an antineoplastic agent, prescribed for prostate cancer with prednisone. (medindia.net)
Tumor cells1
- This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. (wikimd.org)
Antitumor1
- Rabusertib binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. (wikimd.org)
Protocols1
- Glucocorticoids are considered cell-cycle nonspecific and are often used in chemotherapeutic protocols after induction by another agent. (merckvetmanual.com)
Neoplastic cells2
- However, evidence from several sources suggests that treatment of certain lymphomas with prednisone may increase resistance of neoplastic cells to subsequent cycles of antineoplastic chemotherapy through induction of MDR-1-related P-glycoprotein expression. (merckvetmanual.com)
- These findings led to investigation of metformin in preclinical cancer models, most of which demonstrate clear antineoplastic effects that are attributable to direct action on neoplastic cells and/or indirect effects resulting from alterations in the hormonal milieu ( 2 , 5-7 ). (aacrjournals.org)
Medication8
- The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is written by the provider and when the medication is received by the patient and to identify risk factors that significantly increase time to medication receipt. (hindawi.com)
- This medication is a chemotherapy agent, prescribed for non-small cell lung cancer. (medindia.net)
- This medication is an alkylating agent, prescribed for chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL). (medindia.net)
- This medication is an alkylating agent, prescribed for certain types of cancer. (medindia.net)
- This medication is a synthetic anti-cancer agent, prescribed for hairy cell leukemia. (medindia.net)
- This medication is an anticancer agent, prescribed for lymphoma. (medindia.net)
- This medication is a hormonal chemotherapy agent, prescribed for malignant neoplasms. (medindia.net)
- This medication is an anti-cancer agent, prescribed for certain type of leukemia in people who are at least 60 years old. (medindia.net)
Contraceptive1
- Essentially, the hormonal contraceptive inhibits the entire male reproductive system, more specifically primary male sexual characteristics. (usc.edu)
Chemotherapeutic1
- Know the relative onset, duration, and severity of nausea and vomiting with different chemotherapeutic agents. (arizona.edu)
Metastatic1
- Na17.A2 Peptide vaccine - A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. (wikimd.org)
Treatment5
- CONCLUSIONS: As in other countries, in Korea LAM occurs exclusively in women and progresses despite hormonal treatment. (biomedsearch.com)
- It is the most widely prescribed antineoplastic hormonal treatment agent today. (aacrjournals.org)
- For the past several decades, cancer treatment has entailed primarily intravenous delivery of antineoplastic agents. (hindawi.com)
- The use of oral antineoplastic agents for cancer treatment removes the routine and continuous monitoring that was included with intravenous treatment. (hindawi.com)
- Metformin, a biguanide widely used in the treatment of type II diabetes, clearly exhibits antineoplastic activity in experimental models and has been reported to reduce cancer incidence in diabetics. (aacrjournals.org)
Chemical1
- These changes are the result of the interaction between an individual's genetic make-up and external agents including physical, chemical, and biological carcinogens [ 2 ]. (intechopen.com)
Antigen1
- Na-17/mage-3.A2/ny-eso-1 peptide vaccine - A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. (wikimd.org)
Paclitaxel2
- The study demonstrated externally verified response rates of 20.5% (23/122) for topotecan and 14% (15/114) for paclitaxel with similar progression-free and overall survival for the two agents [19]. (dailystrength.org)
- Nab-paclitaxel - A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. (wikimd.org)
Experimental1
- Experimental data indicate that the action of Vinblastine sulfate is different from that of other recognized antineoplastic agents. (drugs.com)
Synthetic1
- A synthetic estrogen that has been used as a hormonal antineoplastic agent. (drugbank.com)
Clinical Trials1
- Accordingly, our goals were to identify and characterize single and combination agents having anti-GBM activity that we can potentially introduce into clinical trials quickly. (biomedcentral.com)
Oral7
- First-time fill prescriptions for oral antineoplastic agents were identified. (hindawi.com)
- An understanding of the median time involved, as well as factors affecting the time to delivery of prescriptions, will help healthcare providers better plan and prepare for the use of oral antineoplastic agents. (hindawi.com)
- However, in recent years, the use of oral antineoplastic agents has steadily increased among patients with a cancer diagnosis. (hindawi.com)
- With the increasing use of oral agents, patients now have more responsibility for monitoring and reporting side effects to their health care providers [ 3 , 7 ]. (hindawi.com)
- While they have the added benefit of convenience, most new oral antineoplastic agents are more expensive than traditional intravenous chemotherapy. (hindawi.com)
- Due to the increased costs associated with oral antineoplastic agents, many pharmacy benefit plans have implemented cost-containment mechanisms [ 3 , 7 ]. (hindawi.com)
- With the average cost of a new oral antineoplastic drug in 2012 approximating $10,000, paying for medications can be a significant out-of-pocket expense and burden for patients. (hindawi.com)
Drug2
- A large single hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. (bioportfolio.com)
- Large-scale studies of Drug Provocation Testing (DPT) or Rapid Drug Desensitization (RDD) for hypersensitivity to antineoplastics and biologicals are scarce and limited to a few institutions OBJECTIVE. (bioportfolio.com)
Pharmacological1
- A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. (drugbank.ca)